- KEYNOTE-B96 is the first trial to show significant OS improvement in platinum-resistant ovarian cancer.
- The trial involved KEYTRUDA combined with chemotherapy, with or without bevacizumab.
- Results will be presented at the European Society for Medical Oncology Congress 2025.
Trial Overview
The Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluated the efficacy of KEYTRUDA (pembrolizumab) in combination with chemotherapy, with or without bevacizumab, for patients with platinum-resistant recurrent ovarian cancer.
Key Findings
The trial met its secondary endpoint of overall survival (OS) in all comers, showing a statistically significant and clinically meaningful improvement compared to placebo plus chemotherapy, with or without bevacizumab. The primary endpoint of progression-free survival (PFS) was also previously met.
Safety Profile
The safety profile of KEYTRUDA in this trial was consistent with previous studies, with no new safety signals identified.
Future Presentations
Findings from the trial will be presented at the European Society for Medical Oncology (ESMO) Congress 2025 and an upcoming medical meeting.
